24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
Spotlight
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
ADHD
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
13:05
NextVision hits $5 billion valuation after landing record $77 million drone camera deal
12:29
Navan shares extend decline as losses widen and CFO plans exit
09:55
The calm town at the center of the quantum race
09:24
The OpenAI security breach: The information you share with ChatGPT may leak
More stories
Buzz
Most popular
Daily
Weekly
1
“Younger people are getting cancer more and more. We have to make kinder medicines.”
2
The $2.3 billion mystery arms deal Israel won’t explain
3
Shipping giant MSC submits bid for ZIM, challenging Hapag-Lloyd in takeover race
4
“The acquisition of Armis marks a clear entry by ServiceNow into cybersecurity”
5
Armis sale to ServiceNow could yield $4 billion windfall for Insight Partners
More news
ADHD
4 stories about ADHD
“There are so few female founders; this has to be put in the past”
21.08.24
|
Ariela Karmel
Eve Mamane, Co-Founder and CRO of mental health startup Agave Health, spoke to CTech about founding her first venture, the need to normalize female founders, and why the tech industry must eliminate outdated limitations on women in leadership roles
Israeli app launches in the U.S. and Israel, helping parents of ADHD children
15.01.24
|
James Spiro
Pery uses clinical data and LLMs to provide advice and analysis for parents managing children diagnosed with attention deficit hyperactivity disorder
“There is a $5 billion opportunity in the ADHD market”
30.01.23
|
CTech
MindTension has raised a total of $2 million for its tool helping diagnose and treat optimization of ADHD and related mental health comorbidities
Teva Reaches Confidential Patent Settlement with Neos
27.12.18
|
CTech
The agreement will enable Teva to manufacture and sell a generic version of Neos’ ADHD drug Cotempla as of 2026